
Scholar Rock Holding Corporation (NASDAQ:SRRK – Free Report) – Research analysts at HC Wainwright boosted their FY2026 earnings per share estimates for shares of Scholar Rock in a research note issued on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($3.23) per share for the year, up from their previous estimate of ($3.30). HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($3.04) per share. HC Wainwright also issued estimates for Scholar Rock’s Q4 2026 earnings at ($0.75) EPS, FY2027 earnings at ($2.66) EPS, FY2028 earnings at ($1.39) EPS, FY2029 earnings at ($0.12) EPS and FY2030 earnings at $1.00 EPS.
Scholar Rock (NASDAQ:SRRK – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The company had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.30 million. During the same quarter in the prior year, the company earned ($0.90) EPS.
View Our Latest Stock Analysis on Scholar Rock
Scholar Rock Trading Up 0.1%
SRRK opened at $43.21 on Thursday. The firm’s 50 day moving average is $46.13 and its 200-day moving average is $48.22. Scholar Rock has a 52-week low of $34.25 and a 52-week high of $61.76. The company has a quick ratio of 7.02, a current ratio of 5.41 and a debt-to-equity ratio of 1.16. The firm has a market capitalization of $5.27 billion, a P/E ratio of -12.86 and a beta of 0.78.
Institutional Trading of Scholar Rock
A number of hedge funds have recently made changes to their positions in SRRK. Headlands Technologies LLC bought a new stake in shares of Scholar Rock in the third quarter worth $430,000. First Trust Advisors LP raised its holdings in Scholar Rock by 17.2% in the third quarter. First Trust Advisors LP now owns 8,292 shares of the company’s stock valued at $401,000 after acquiring an additional 1,217 shares in the last quarter. GW&K Investment Management LLC acquired a new stake in Scholar Rock in the third quarter valued at $17,534,000. Voya Investment Management LLC raised its holdings in Scholar Rock by 4.8% in the third quarter. Voya Investment Management LLC now owns 933,359 shares of the company’s stock valued at $45,100,000 after acquiring an additional 42,752 shares in the last quarter. Finally, Public Sector Pension Investment Board bought a new position in Scholar Rock during the 3rd quarter valued at $3,044,000. Institutional investors and hedge funds own 91.08% of the company’s stock.
Insider Transactions at Scholar Rock
In other Scholar Rock news, Director Srinivas Akkaraju bought 146,970 shares of the business’s stock in a transaction on Monday, October 26th. The shares were bought at an average cost of $41.59 per share, with a total value of $6,112,482.30. Following the transaction, the director directly owned 6,380,517 shares in the company, valued at approximately $265,365,702.03. This trade represents a 2.36% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 10.30% of the stock is owned by corporate insiders.
Scholar Rock News Summary
Investors following SRRK have been watching these news items:
- Positive Sentiment: HC Wainwright raised its Q4 2026 EPS estimate to a loss of $0.75 from $0.78 and its FY2026 estimate to a loss of $3.23 from $3.30. The firm maintained its Buy rating and $70 price target. HC Wainwright Predicts Scholar Rock Q1 Earnings
- Negative Sentiment: Wolfe Research downgraded SRRK from Outperform to Peer Perform, removing a bullish rating signal. Wolfe Research ratings
- Negative Sentiment: HC Wainwright cut estimates for FY2027–FY2030: its FY2029 forecast shifted from $0.47 in earnings per share to a $0.12 loss, while its FY2030 forecast fell from $1.44 to $1.00. These longer-range cuts temper the improved near-term outlook. Scholar Rock analyst estimates
About Scholar Rock
Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation. The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.
Featured Articles
- Five stocks we like better than Scholar Rock
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.
